2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Novel Drug Delivery Systems market for 2018-2023.
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
The classification of Novel Drug Delivery Systems includes Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein–drug Conjugates, and the proportion of PEGylated Proteins & Polypeptides in 2017 is about 39.60%, and the proportion is in decreasing trend from 2013 to 2017.
North America is the largest consumption place, with a consumption market share nearly 49.69% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 26.15%.
Over the next five years, LPI(LP Information) projects that Novel Drug Delivery Systems will register a 2.2% CAGR in terms of revenue, reach US$ 30300 million by 2023, from US$ 26500 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Novel Drug Delivery Systems market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Segmentation by application:
Hospitals & Clinic
Cancer Treatment Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Amgen
Teva
UCB (Union Chimique Belge)
Roche
Celgene
Sanofi
Merck
Johnson & Johnson
Takeda
Gilead Sciences
Pfizer
Dr Reddy
Samyang Biopharmaceuticals
TOLMAR
Astellas
AMAG Pharmaceuticals
AstraZeneca
AbbVie
Bausch＆Lomb
TWi Pharmaceuticals
Novartis
Aspen
Shire
Breckenridge Pharmaceuticals
Galen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Novel Drug Delivery Systems consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Novel Drug Delivery Systems market by identifying its various subsegments.
Focuses on the key global Novel Drug Delivery Systems manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Novel Drug Delivery Systems with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Novel Drug Delivery Systems submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Novel Drug Delivery Systems Consumption 2013-2023
2.1.2 Novel Drug Delivery Systems Consumption CAGR by Region
2.2 Novel Drug Delivery Systems Segment by Type
2.2.1 Liposomes
2.2.2 PEGylated Proteins & Polypeptides
2.2.3 Polymer Nanoparticle
2.2.4 Protein–drug Conjugates
2.2.5 Others
2.3 Novel Drug Delivery Systems Consumption by Type
2.3.1 Global Novel Drug Delivery Systems Consumption Market Share by Type (2013-2018)
2.3.2 Global Novel Drug Delivery Systems Revenue and Market Share by Type (2013-2018)
2.3.3 Global Novel Drug Delivery Systems Sale Price by Type (2013-2018)
2.4 Novel Drug Delivery Systems Segment by Application
2.4.1 Hospitals & Clinic
2.4.2 Cancer Treatment Centers
2.4.3 Others
2.5 Novel Drug Delivery Systems Consumption by Application
2.5.1 Global Novel Drug Delivery Systems Consumption Market Share by Application (2013-2018)
2.5.2 Global Novel Drug Delivery Systems Value and Market Share by Application (2013-2018)
2.5.3 Global Novel Drug Delivery Systems Sale Price by Application (2013-2018)
3 Global Novel Drug Delivery Systems by Players
3.1 Global Novel Drug Delivery Systems Sales Market Share by Players
3.1.1 Global Novel Drug Delivery Systems Sales by Players (2016-2018)
3.1.2 Global Novel Drug Delivery Systems Sales Market Share by Players (2016-2018)
3.2 Global Novel Drug Delivery Systems Revenue Market Share by Players
3.2.1 Global Novel Drug Delivery Systems Revenue by Players (2016-2018)
3.2.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2016-2018)
3.3 Global Novel Drug Delivery Systems Sale Price by Players
3.4 Global Novel Drug Delivery Systems Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Novel Drug Delivery Systems Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Novel Drug Delivery Systems Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Novel Drug Delivery Systems by Regions
4.1 Novel Drug Delivery Systems by Regions
4.1.1 Global Novel Drug Delivery Systems Consumption by Regions
4.1.2 Global Novel Drug Delivery Systems Value by Regions
4.2 Americas Novel Drug Delivery Systems Consumption Growth
4.3 APAC Novel Drug Delivery Systems Consumption Growth
4.4 Europe Novel Drug Delivery Systems Consumption Growth
4.5 Middle East & Africa Novel Drug Delivery Systems Consumption Growth
5 Americas
5.1 Americas Novel Drug Delivery Systems Consumption by Countries
5.1.1 Americas Novel Drug Delivery Systems Consumption by Countries (2013-2018)
5.1.2 Americas Novel Drug Delivery Systems Value by Countries (2013-2018)
5.2 Americas Novel Drug Delivery Systems Consumption by Type
5.3 Americas Novel Drug Delivery Systems Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Novel Drug Delivery Systems Consumption by Countries
6.1.1 APAC Novel Drug Delivery Systems Consumption by Countries (2013-2018)
6.1.2 APAC Novel Drug Delivery Systems Value by Countries (2013-2018)
6.2 APAC Novel Drug Delivery Systems Consumption by Type
6.3 APAC Novel Drug Delivery Systems Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Novel Drug Delivery Systems by Countries
7.1.1 Europe Novel Drug Delivery Systems Consumption by Countries (2013-2018)
7.1.2 Europe Novel Drug Delivery Systems Value by Countries (2013-2018)
7.2 Europe Novel Drug Delivery Systems Consumption by Type
7.3 Europe Novel Drug Delivery Systems Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Novel Drug Delivery Systems by Countries
8.1.1 Middle East & Africa Novel Drug Delivery Systems Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Novel Drug Delivery Systems Value by Countries (2013-2018)
8.2 Middle East & Africa Novel Drug Delivery Systems Consumption by Type
8.3 Middle East & Africa Novel Drug Delivery Systems Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Novel Drug Delivery Systems Distributors
10.3 Novel Drug Delivery Systems Customer
11 Global Novel Drug Delivery Systems Market Forecast
11.1 Global Novel Drug Delivery Systems Consumption Forecast (2018-2023)
11.2 Global Novel Drug Delivery Systems Forecast by Regions
11.2.1 Global Novel Drug Delivery Systems Forecast by Regions (2018-2023)
11.2.2 Global Novel Drug Delivery Systems Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Novel Drug Delivery Systems Forecast by Type
11.8 Global Novel Drug Delivery Systems Forecast by Application
12 Key Players Analysis
12.1 Amgen
12.1.1 Company Details
12.1.2 Novel Drug Delivery Systems Product Offered
12.1.3 Amgen Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Amgen News
12.2 Teva
12.2.1 Company Details
12.2.2 Novel Drug Delivery Systems Product Offered
12.2.3 Teva Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Teva News
12.3 UCB (Union Chimique Belge)
12.3.1 Company Details
12.3.2 Novel Drug Delivery Systems Product Offered
12.3.3 UCB (Union Chimique Belge) Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 UCB (Union Chimique Belge) News
12.4 Roche
12.4.1 Company Details
12.4.2 Novel Drug Delivery Systems Product Offered
12.4.3 Roche Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Roche News
12.5 Celgene
12.5.1 Company Details
12.5.2 Novel Drug Delivery Systems Product Offered
12.5.3 Celgene Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Celgene News
12.6 Sanofi
12.6.1 Company Details
12.6.2 Novel Drug Delivery Systems Product Offered
12.6.3 Sanofi Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Sanofi News
12.7 Merck
12.7.1 Company Details
12.7.2 Novel Drug Delivery Systems Product Offered
12.7.3 Merck Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Merck News
12.8 Johnson & Johnson
12.8.1 Company Details
12.8.2 Novel Drug Delivery Systems Product Offered
12.8.3 Johnson & Johnson Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Johnson & Johnson News
12.9 Takeda
12.9.1 Company Details
12.9.2 Novel Drug Delivery Systems Product Offered
12.9.3 Takeda Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Takeda News
12.10 Gilead Sciences
12.10.1 Company Details
12.10.2 Novel Drug Delivery Systems Product Offered
12.10.3 Gilead Sciences Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Gilead Sciences News
12.11 Pfizer
12.12 Dr Reddy
12.13 Samyang Biopharmaceuticals
12.14 TOLMAR
12.15 Astellas
12.16 AMAG Pharmaceuticals
12.17 AstraZeneca
12.18 AbbVie
12.19 Bausch＆Lomb
12.20 TWi Pharmaceuticals
12.21 Novartis
12.22 Aspen
12.23 Shire
12.24 Breckenridge Pharmaceuticals
12.25 Galen
13 Research Findings and Conclusion
